Eddie Pharmaceuticals plans to raise 1.277 billion yuan to promote the global clinical development of a new HIV drug

MaticHoleFiller · 2026-03-24T10:46:43+00:00

Aidi Pharmaceuticals recently announced a private placement plan, aiming to raise no more than 1.277 billion yuan to fund the development of new HIV drugs and equity acquisitions. The company has also obtained the new drug registration certificate, leading to increased market attention. The stock has experienced significant short-term fluctuations, but its overall performance remains relatively stable.

MaticHoleFiller

2026-03-24 10:46:43

Abstract generation in progress

Economic Observer Network - Aidi Pharmaceutical recently disclosed a large-scale private placement plan and received a registration certificate for a new anti-HIV drug, attracting market attention.

Recent Events

Recently, Aidi Pharmaceutical (688488.SH) has focused on strategic financing and product development. On March 13, 2026, the company announced a private placement plan to raise no more than 1.277 billion yuan from no more than 35 specific investors, mainly for global clinical development of a new HIV integrase inhibitor (INSTI) (accounting for over 60%), acquiring a 22.2324% stake in Nanda Pharmaceutical, and supplementing working capital. This plan replaces the previously announced 185 million yuan simple private placement on January 13, with nearly a sevenfold increase in fundraising, highlighting the company’s urgent funding needs and its focus on internationalization strategy. On March 16, 2026, the company announced it had received the drug registration certificate for Dolutegravir sodium tablets approved by the National Medical Products Administration, enriching its anti-HIV product line and potentially enhancing competitiveness. Meanwhile, institutional research activity was active, with Yihu Investment and Jiupeng Asset participating in the analyst meeting on March 13, focusing on the overseas development progress of pipeline products like ACC017.

Recent Stock Performance

Over the past 7 trading days (March 10 to 17, 2026), Aidi Pharmaceutical’s stock price experienced significant fluctuations. On March 10, it surged 8.94% to 17.67 yuan, with trading volume increasing to 134,800 lots; on March 13, following the announcement of the private placement, the stock fell 4.87% to 16.03 yuan, with a 2.00% turnover rate; it then rebounded, rising 1.50% on March 16, and closing at 16.30 yuan on March 17, up 0.18%. The total increase over the period was 0.49%, with an amplitude of 11.04%, and total trading volume of 822 million yuan. On March 17, the main funds saw a net inflow of 6.7 million yuan, while retail funds showed a net outflow. During the same period, the biotech and pharmaceutical sector declined slightly by 0.74%, and the company’s stock performance was relatively resilient.

The above content is compiled from public information and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.